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del(12)(p11p13) G-banding (left) Courtesy Jean-Luc Lai and 
Alain Vanderhaegen; R-banding (right) - Editor (below); 
Courtesy Jean-Luc Lai (above). 
Clinics and pathology 
Epidemiology 
12p abnormalities are common in a broad spectrum of 
haematological malignancies (acute lymphoblastic 
(ALL) or acute myeloid (ANLL) leukaemias, 
myelodysplastic (MDS) or chronic myeloproliferative 
syndromes, non-Hodgkin's lymphomas; observed in 
about 5% of acute non lymphocytic leukaemias and 
myelodysplastic syndromes; characteristic of secondary 
leukaemia after prior mutagenic exposure (10%) and 




- Sole anomaly in 20%; numerical and structural 
rearrangements of chromosomes 5 and 7 frequently 
associated (found in 50% in de novo cases). 
- del(12p): due to the very heterogeneous breakpoints 
in 12p (assigned to all chromosome bands), no 
cytogenetic subgroups are defined; deletion in 12p is 
generally associated with a poor prognosis; however, 
different clinical courses are defined concerning the 
magnitude of 12p; a group with small deletions has a 
better prognosis than patients with 12p abnormalities in 
general and a lower tendency to additional 
chromosomal rearrangements; submicroscopic 
deletions of 12p are much more common in lymphoid 
than in myeloid malignancies; a minimal interstitial 
deletion region is described, involving ETV6 and 
CDKN1B genes; homozygous deletion of CDKN1B is 
rare (the other wild allele never found mutated); none 
of the malignancies with disease specific changes 
displayed submicroscopic 12p deletions. 
- dup(12)(p11.2p13) described in one MDS case after 
benzole agent exposure. 
- Additions are frequent, considered as imbalanced 
translocations. 
- Translocations: translocations or dicentrics involving 
12p are mostly associated with loss of 12p material; a 
lot of partner bands are described; chromosome 12 
breakpoint is most often localized in 12p13, involving 
ETV6 gene, with fusion of 5' end of ETV6 with 3' end 
of the partner, and sometimes accompanied with a 
concomitant deletion of the other ETV6 allele: 
- t(3;12)(q23;p12.3): described as reciprocal and 
recurrent, involving ETV6 (heterogeneous breakpoints 
described) and EVI1, and associated with a poor 
prognosis. 
- t(4;12)(q11q13;p12;p13): associated with specific 
clinical features: CD7-positive ANLL, three-lineage 
dysplasia, blood and bone marrow basophilia. 
- t(5;12)(q33;p13): recurrent, described in chronic 
myelomonocytic leukemia: fusion between HLH 
domain of ETV6 and transmembrane and cytoplasmic 
kinase domains of PDGFRb; a variant 
t(10;12)(q24;p13) is described in MDS in progression 
with eosinopilia and monocytosis. 
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- t/dic(12;13): representing up to 20% of 12p 
rearrangements in one study, associated with a poor
prognosis. 
- t(12;22)(p13;q11): resulting in MN1-ETV6 fusion 
gene (where breakpoint, 5' of, or in, ETV6 HLH 
domain, is the sole exception), and reported in myeloid 
malignancies (ANLL and MDS). 
- other translocations involving ETV6: 
t(5;12)(q31;p12) in 'atypical CML', t(6;12)(p21;p13) in 
MDS, t(7;12)(p15;p13), t(7;12)(q36;p13) in ANLL, 
t(9;12;14)(q34;p13;q22) in ANLL,... and the never-up-
to-date following list: t(6;12)(q23;p13), 
t(12;17)(p11.2;q11), t/dic(12;20)(p12-p13;p11.2-q13), 
i(12p) where implication of ETV6 gene is not yet 
proven. 
Probes 
From telomere to centromere: 
Corresponding to D12S1455: PAC9015; 
To CCND2: C139C5, C140H4, C146H1, C213C1; 
To PRB: CPRB; 
To ETV6: yacs 958B8, 964C10, cosmids: C5OF4, 
C163E7, C179AB(5'), C148B6(3'); 
To CDKN1B: 123C12, 142C5; 
To KRAS2: 153F12. 
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